CNJ.TO  Cangene Cp

Exchange

TSX

Sector

Life Sciences

Industry

Market Cap.

240.3M

Vuru Grade

39.25/100

Current Price

$3.60
0.00 (0.00%)

Growth Price

$4.10
Undervalued by 13.88%

Stability Price

$2.79
Overvalued by 22.48%

Company Metrics

  • 169 P/E
  • 2.08 P/S
  • 1.25 P/B
  • -0.15 EPS
  • 5.09% Cash ROIC
  • 1.68 Cash Ratio
  • 0 / 0% Dividend
  • 255,197.00 Avg. Vol.
  • 66.75M Shares
  • 240.3M Market Cap.

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire (press release) - Feb 21, 2014
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects ...
Cangene Announces Completion of Acquisition by Emergent BioSolutions - Canada NewsWire (press release)
Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp.
Washington Post - Dec 11, 2013
Emergent BioSolutions established itself as a leading biodefense company by selling Anthrax vaccines en masse to the federal government in the wake of Sept.
Emergent Bio (EBS) to Acquire Cangene Corp in $222M Deal - StreetInsider.com (subscription)
Emergent BioSolutions strikes $222M deal to buy Cangene Corp. - Baltimore Sun
Cangene takeover might not be a bad thing
Winnipeg Free Press - Dec 20, 2013
The recently announced proposed sale of Cangene Corp. to Emergent BioSolutions Inc. of Maryland for $222 million is bringing up those concerns once again.
Cangene To Be Acquired By Emergent BioSolutions For US$222 Million
Canada NewsWire (press release) - Dec 11, 2013
11, 2013 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) today announced the signing of a definitive agreement under which Emergent BioSolutions ("Emergent") (NYSE: EBS) of Rockville, Maryland will acquire Cangene in an all-cash transaction ...
CANGENE bioPHARMA FACILITY RENOVATION IS COMPLETE AND ...
PR Newswire (press release) - May 2, 2011
BALTIMORE AND WINNIPEG, May 2 /PRNewswire/ - Cangene Corporation's Baltimore-based injectable pharmaceutical contract-manufacturing subsidiary, Cangene bioPharma, Inc., has completed a US$11-million renovation of its sterile filling and support ...
Cangene receives marketing authorization approval for WinRho 1500 LQ in ...
Canada NewsWire (press release) - Sep 11, 2013
WINNIPEG, Sept. 11, 2013 /CNW/ - Cangene Corporation (Cangene) announced today that the company's wholly owned subsidiary, Cangene Europe Limited, received marketing authorization approval for WinRho┬« 1500 LQ in Portugal from the National ...
FDA lifts clinical hold on Cangene's hemophilia compound IB1001
Canada NewsWire (press release) - Jul 29, 2013
WINNIPEG, July 29, 2013 /CNW/ - Cangene Corporation (Cangene) today announces that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on clinical trials evaluating the safety and efficacy of IB1001, a recombinant ...
Cangene Shareholders Approve Acquisition by Emergent BioSolutions
Canada NewsWire (press release) - Feb 13, 2014
13, 2014 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) announced that its shareholders have approved the previously announced acquisition by Emergent BioSolutions ("Emergent") (NYSE: EBS) at a special meeting held today.
Cangene shareholders approve sale to Emergent BioSolutions - Winnipeg Free Press
Ipsen and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale ...
Business Wire (press release) - Feb 20, 2013
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) and Inspiration Biopharmaceuticals Inc. (Inspiration) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene).
Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to ... - News-Medical.net
Cangene Reports Fiscal 2013 Results; Net Income Up $29.6 million from Prior ...
Canada NewsWire (press release) - Oct 30, 2013
WINNIPEG, Oct. 29, 2013 /CNW/ - Cangene Corporation ("Cangene") today reports its financial results for the year ended July 31, 2013.